findmyKOL
Clinical trialNCT06206512CompletedPhase 2Interventional

Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder

SponsorSarfez Pharmaceuticals, Inc.Enrollment24Heart FailureIncontinenceOveractive Bladder
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Cardiometabolic Research Unit

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
15 Jun 2024
Primary completion
17 Nov 2025
Completion
9 Mar 2026
Last update posted
12 Mar 2026
Registered enrollment
24
Registry id
NCT06206512

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.